NovaBay Pharmaceuticals, Inc. Research and Development (R&D) Expenses Growth

Research and Development (R&D) Expenses Growth of NBY for past 10 years: annual, quarterly and twelve month trailing (TTM) including Research and Development (R&D) Expenses Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Research and Development (R&D) Expenses Growth for the quarter ending September 30, 2022 was 310.0% (a 242.62% increase compared to previous quarter)
  • Year-over-year quarterly Research and Development (R&D) Expenses Growth decreased by -498.56%
  • Annual Research and Development (R&D) Expenses Growth for 2021 was -84.56% (a -254.05% decrease from previous year)
  • Annual Research and Development (R&D) Expenses Growth for 2020 was 54.89% (a -289.54% decrease from previous year)
  • Annual Research and Development (R&D) Expenses Growth for 2019 was -28.96% (a -21.37% decrease from previous year)
  • Twelve month Research and Development (R&D) Expenses Growth ending September 30, 2022 was 62.5% (a -215.72% decrease compared to previous quarter)
  • Twelve month trailing Research and Development (R&D) Expenses Growth decreased by -173.91% year-over-year
Trailing Research and Development (R&D) Expenses Growth for the last four month:
30 Sep '22 30 Jun '22 31 Mar '22 31 Dec '21
62.5% -54.01% -76.16% -84.56%
Visit stockrow.com/NBY for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Research and Development (R&D) Expenses Growth of NovaBay Pharmaceuticals, Inc.

Most recent Research and Development (R&D) Expenses Growthof NBY including historical data for past 10 years.

Interactive Chart of Research and Development (R&D) Expenses Growth of NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc. Research and Development (R&D) Expenses Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 310.0% 90.48% 460.0%
2021 -77.78% -92.0% -81.74% -44.44% -84.56%
2020 100.0% 155.1% 259.38% -89.41% 54.89%
2019 -83.18% 8.89% -47.54% 84.78% -28.96%
2018 -26.71% -65.91% -12.86% -25.81% -36.83%
2017 -6.41% 3200.0% -74.82% -93.35% -70.09%
2016 -87.27% -99.74% -79.51% -41.06% -76.06%
2015 -48.64% -32.4% -39.37% -37.87% -39.6%
2014 -41.63% -8.0% -23.8% -12.89% -23.9%
2013 92.83% -0.04% 23.51% 29.2% 34.35%
2012 -3.64% 24.27% -14.12% -22.47% -6.42%
2011 9.46% 15.03%

Business Profile of NovaBay Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology